Evidence map›Paper›PMID 40624508›Full record

ReviewJournal of nanobiotechnology2025

Recent advances of engineering cell membranes for nanomedicine delivery across the blood-brain barrier.

Shengnan Yuan, Dehong Hu, Duyang Gao, Christopher J Butch, Yiqing Wang, Hairong Zheng, Zonghai Sheng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shengnan YuanResearch Center for Advanced Detection Materials and Medical Imaging Devices, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Dehong HuResearch Center for Advanced Detection Materials and Medical Imaging Devices, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Duyang GaoResearch Center for Advanced Detection Materials and Medical Imaging Devices, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Christopher J ButchDepartment of Biomedical Engineering, College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, 210023, P. R. China.
Yiqing WangDepartment of Biomedical Engineering, College of Engineering and Applied Sciences, State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, 210023, P. R. China.
Hairong ZhengResearch Center for Advanced Detection Materials and Medical Imaging Devices, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China.
Zonghai ShengResearch Center for Advanced Detection Materials and Medical Imaging Devices, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, P. R. China. zh.sheng@siat.ac.cn.

Funding

Guangdong Basic and Applied Basic Research Fund 2024A1515030212, 2023A1515010747, 2023A1515140133, and 2022A1515140102National Key Research and Development Program of China no. 2023YFF0714200Natural Science Foundation of China 92159304, 82372022, 82227806, and 82171958Shenzhen Medical Research Funds B2302021 and E3A1051001
6 · The paper itself

Abstract

The blood-brain barrier (BBB) poses a major challenge to the effective delivery of therapeutic agents for the treatment of central nervous system (CNS) disorders. The integration of cell membrane engineering with nanotechnology has recently enabled the development of membrane-engineered nanoparticles (CNPs). These nanocarriers exhibit enhanced BBB penetration and improved CNS targeting. This review systematically summarizes the latest advances in the development and application of CNPs, emphasizing how different cellular sources-such as erythrocytes, platelets, tumor cells, and leukocytes-impact delivery efficiency and therapeutic outcomes. We also examine the molecular mechanisms underlying nanoparticle-BBB interactions and highlight the importance of biosafety evaluations. Moreover, critical barriers to clinical translation, including large-scale manufacturing challenges, batch-to-batch variability, and regulatory complexities, are discussed. Finally, we explore emerging strategies-particularly the integration of artificial intelligence (AI)-that hold potential for overcoming existing clinical gaps, enabling the rational design and optimized development of CNP-based therapeutics for CNS disorders. By integrating mechanistic insights with translational perspectives, this review provides a clear conceptual and technological foundation for the development of next-generation CNS-targeted nanotherapeutics.

Indexed as

Blood-Brain BarrierCell MembraneDrug Delivery SystemsNanomedicineAnimalsCentral Nervous System DiseasesHumansNanoparticles

Identifiers

PMID40624508
PMCPMC12235962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.